After an elongated interval, Sun pharmaceutical industries finally get a nod from the US health regulator to perform business with the generic version of Doxic injection, which is essential for treating ovarian cancer, basically in the US market. According to the sources of the firm in Mumbai headquarters explained that the subsidiary had been approved from the US Food & Drug Administration (USFDA), mainly for the Doxorubicin HCI Liposome Injection.
The company stated that the generic Doxorubicin HCI liposome Injection USP, 2mg/ml, is medically equivalent to Doxil Liposome injection, 2mg/ml of Janssen R&D. This anti-cancer injection plays a vital role in curing patients possessing ovarian cancer that has occurred again after platinum-based chemotherapy.
Shares of the company were functioning at according to Bombay Stock Exchange & the net profit accelerated to $89 million. Net sales of the same in December 2012 have been $186 million.